MetaCap

Alvotech (ALVO) vs Windward Bio Group (WWB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alvotech is the larger company by market cap ($1.47 billion vs $1.45 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALVO-1.67%WWB-14.79%
+10%-6%-22%
Nov 13, 20261 yearNov 20, 2026
ALVO-1.67%WWB-14.79%
+1%-7%-16%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALVO versus WWB key metrics
MetricALVOWWB
Share price$4.12$24.29
Market cap$1.47B$1.45B
1-day change-3.96%+1.15%
YTD return-19.69%—
1-year return-19.84%—
Forward P/E19.46—
EPS (TTM)$-0.82$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$586.32M—
Revenue growth (YoY)+19.74%—
Net income (latest FY)$27.92M—
Gross margin59.82%—
Operating margin13.34%—
Net margin4.76%—
52-week high$6.53$33.99
52-week low$2.94$18.35
Distance from 52-week high-36.91%-28.55%
Analyst consensusbuy—
Avg. price target upside+82.04%—
Average volume1.13M434.33K
Shares outstanding356.82M59.58M
Employees1,27933
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Alvotech

ALVO stock →

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees

About Windward Bio Group

WWB stock →

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees

ALVO vs WWB FAQ

Which is bigger, Alvotech or Windward Bio Group?

Alvotech (ALVO) is larger, with a market capitalization of $1.47B compared with $1.45B for Windward Bio Group (WWB).

Are Alvotech and Windward Bio Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons